- Company
- AML treatment Rydapt can be prescribed in general hospitals
- by Eo, Yun-Ho Jul 3, 2020 06:18am
- Novartis' new acute myelogenous leukemia drug 'Rydapt' can be prescribed in general hospitals. According to the related industry, acute myeloid leukemia (AML) treatment, Rydapt (Midostaurin) has passed the pharmaceutical committee (DC, drug commitee) of Big 5 Hospitals, such as Seoul National University Hospital and AMC. It was approved
- Company
- Lee Heeseung to oversee MA-GA-PR at MSD Korea
- by Eo, Yun-Ho Jul 2, 2020 06:09am
- A former senior director at Novartis Korea, Lee Heeseung is to be appointed as a leader of the External Affairs department at MSD Korea. According to the pharmaceutical industry sources told the latest personnel decision by MSD Korea. Lee Heeseung would take over the position of External Affairs Lead from July 15. Three teams includi
- Company
- Nicetile's Rx has decreased by 40% over the past year
- by Chon, Seung-Hyun Jul 2, 2020 06:08am
- Sales of 'Acetyl-L-Carnitine (ALC)', a brain function improving agent, fell sharply. As a result of clinical re-evaluation, the market size has decreased by 40% in one year as indications have been reduced. The market for 'Choline alfoscerate', which is predicted for clinical re-evaluation, is also expected to change depending on the results.
- Company
- European license for Avastin biosimilar is imminent.
- by Chon, Seung-Hyun Jul 1, 2020 05:55am
- Samsung Bioepis said on the 28th (local time) that it received a positive opinion on the approval of ‘Avastin biosimilar, Aybintio' from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA). It received positive feedback from the CHMP about 11 months after the launch of EMA's marketing authori
- Company
- Complaint against the plan to reduce benefits of α-GPC
- by Chon, Seung-Hyun Jun 30, 2020 06:11am
- Pharmaceutical companies agreed to file a complaint against the government's plan to reduce the reimbursement of Choline alfoscerate. It is suggested that the co-payment rate be lowered for reasons such as high cognitive impairment and brain-related diseases with high prescription rates. According to the industry on the 29th, more than 100 ex
- Company
- Spravato, a nasal spray for TRD entered the domestic market
- by Eo, Yun-Ho Jun 30, 2020 06:09am
- Spravato is the first nasal spray medication, taken along with an oral antidepressant, for adults with treatment-resistant depression (TRD) and it enters the domestic market. According to the related industry, Janssen’s Spravato nazal spray (Esketamine HCl) as a treatment for moderate to severe major depressive disorder (treatment-resist
- Company
- Prevymis by MSD is noted whether it is listed
- by Eo, Yun-Ho Jun 29, 2020 06:13am
- It is noteworthy whether the coverage for prevention of cytomegalovirus, infection in allogeneic hematopoietic stem cell transplant patients will be expanded. According to related industries, 'Prevymis (Letermovir)', a preventive treatment for cytomegalovirus (CMV) infection in allogeneic hematopoietic stem cell transplant patients, which
- Company
- Boycott Japan: Drug import rather increased in a year
- by Kim, Jin-Gu Jun 29, 2020 06:13am
- During a year of the Koreans boycotting against Japanese-made products, the total imported Japanese pharmaceutical sales have increased even more. But the trade balance has improved as the Korean-made pharmaceuticals exporting to Japan surged as well. Daily Pharm analyzed Korea Customs Service today and found the Japanese-made pharmaceutical
- Company
- Dong-A ST is first to evade antidiabetic Forxiga patent
- by Lee, Tak-Sun Jun 29, 2020 06:13am
- For the first time in Korea, Dong-A ST has successfully evaded pharmaceutical patent on sodium-glucose co-transporter-2 (SGLT-2) inhibiting antidiabetic treatment Forxiga (dapagliflozin) by AstraZeneca. According to the pharmaceutical industry on June 25, Dong-A ST’s request for the negative scope confirmation on two Forxiga patents was
- Company
- New products join the already competitive bowel prep market
- by Lee, in-bok Jun 26, 2020 06:19am
- The bowel preparation market valued at 50 billion won is fluctuating noticeably. New products flooding in just a few years time have overly crowded the market. These products are jumping into the market with improved drug compliance for examinees and patients, but the market has not been easy for them to survive. Three types of bowel
